UK Health Secretary, Sajid Javid, said on Tuesday that the UK had cancelled its contract for about 100 million doses of a COVID-19 vaccine being developed by French biotechnology company Valneva SE (EPA:VLA) in part because it was clear it would not be approved for use in the country, Reuters news agency reported on Wednesday.
Javid was quoted as replying to as Scottish lawmaker: "There are commercial reasons that we have cancelled the contract, but what I can tell her is that it was also clear to us that the vaccine in question that the company was developing would not get approval by the MHRA here in the UK."
The company had said on Monday that the UK had alleged it was in breach of its obligations under the supply agreement. It strenuously denied the charge.
Valneva's vaccine is being produced in Livingston, Scotland, using an adjuvant made by US biopharmaceutical company Dynavax Technologies (Nasdaq:DVAX). The facility has capacity to produce around 200 million doses in 2022.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine